Debt-to-equity of SpringWorks Therapeutics, Inc. from 30 Jun 2020 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
SpringWorks Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2020 to 31 Mar 2025.
  • SpringWorks Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was 17%, a 3.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

SpringWorks Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 17% +0.59% +3.7% 31 Mar 2025
Q4 2024 16% +0.37% +2.4% 31 Dec 2024
Q3 2024 14% -0.01% -0.07% 30 Sep 2024
Q2 2024 15% +2.4% +19% 30 Jun 2024
Q1 2024 16% +3.9% +32% 31 Mar 2024
Q4 2023 15% +4% +35% 31 Dec 2023
Q3 2023 14% +4.6% +48% 30 Sep 2023
Q2 2023 13% +4.6% +58% 30 Jun 2023
Q1 2023 12% +5.8% +93% 31 Mar 2023
Q4 2022 11% +5.9% +110% 31 Dec 2022
Q3 2022 9.7% +5.2% +118% 30 Sep 2022
Q2 2022 8% +3.9% +96% 30 Jun 2022
Q1 2022 6.3% +2.5% +67% 31 Mar 2022
Q4 2021 5.3% +1.7% +47% 31 Dec 2021
Q3 2021 4.4% +0.64% +17% 30 Sep 2021
Q2 2021 4.1% +0.66% +19% 30 Jun 2021
Q1 2021 3.8% 31 Mar 2021
Q4 2020 3.6% 31 Dec 2020
Q3 2020 3.8% 30 Sep 2020
Q2 2020 3.4% 30 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.